JNJ: Strong Fundamentals but Valuation Stretched; Wait for Better Entry

What happened

Johnson & Johnson has delivered a 43% total return over nine months, but a Seeking Alpha article flags that Q1 2026 adjusted operational growth of only 5.3% and a 2.5% decline in adjusted EPS belie the headline 10% sales growth, while management’s double-digit growth target contrasts with consensus ~6% EPS CAGR. The DeepValue Master Report maintains a WAIT rating with conviction 3.5, noting that the next 3–6 months introduce discrete downside catalysts, including the CVS Caremark formulary shift effective July 1, 2026, and potential adverse talc evidentiary rulings. At a P/E of 26.5 and EV/EBITDA of 14.2, the valuation embeds assumptions of orderly STELARA biosimilar erosion and contained talc liability, yet the company itself states it cannot estimate possible talc losses beyond current accruals. The base case valuation of $235 implies limited upside from the current $228.40, while the bear case of $190 highlights the risk if immunology deterioration accelerates or talc costs escalate. Investors should wait for Q2–Q3 FY2026 proof of immunology stabilization and bounded talc exposure before committing capital, as better entry points near $200 would improve forward return asymmetry.

Implication

The current price of $228.40 offers limited upside to the ~$235 base case and embeds optimistic assumptions about STELARA erosion and talc liability. The most likely path over 12–18 months involves near-term headwinds from the July 1 CVS formulary switch and ongoing talc litigation, which could pressure the stock toward the $200 attractive entry level before a cleaner growth profile emerges from TREMFYA IBD launch and oncology scaling. Investors should monitor Q2–Q3 FY2026 results for evidence of immunology stabilization and any talc disclosure shifts; if those confirm the bull case, upgrading at similar prices becomes warranted, but for now patience is prudent.

Thesis delta

The DeepValue thesis remains WAIT with conviction 3.5, but the Seeking Alpha article reinforces the overvaluation concern by highlighting that adjusted EPS declined 2.5% YoY despite strong headline growth. There is no material shift in the thesis; rather the article corroborates the need to wait for a better entry point near $200, as current valuation embeds aggressive assumptions that are unlikely to be met in the near term due to identifiable risk catalysts.